Payment overview · 2025
General Payments
$817.10
58 reported records · 15 companies
Healthcare provider profile · identity verified
Cory E. Rathgeber, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · DICKINSON, ND · NPI 1649367343
Verified facts
What the public records show
CMS Open Payments records show Cory E. Rathgeber, M.D. received $817.10 in general payments during 2025 across 58 reported records.
Amgen Inc. accounted for 22.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Paxlovid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Myrbetriq by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 537 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 291 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 537 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $180.40 | 22.1% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $168.09 | 20.6% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $147.08 | 18.0% | 13 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $62.71 | 7.7% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $47.25 | 5.8% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $41.32 | 5.1% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $32.77 | 4.0% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.17 | 2.7% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $21.77 | 2.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.27 | 2.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.26 | 2.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.32 | 1.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.52 | 1.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.25 | 1.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.92 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $817.10 | 58 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $146.89 | 12 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $136.67 | 12 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $130.38 | 11 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $119.48 | 9 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $62.71 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $60.92 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $60.92 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $47.25 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $42.82 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $32.77 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $26.29 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $21.77 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $21.20 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.32 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.92 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $10.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 537 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 72 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 31 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
537 | 62 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
291 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
72 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
537 | 62 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
31 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1199 | 205 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1161 | 181 |
| Amlodipine Besylate | Amlodipine Besylate | 1138 | 199 |
| Metoprolol Succinate | Metoprolol Succinate | 1044 | 173 |
| Furosemide | Furosemide | 983 | 108 |
| Losartan Potassium | Losartan Potassium | 910 | 187 |
| Lisinopril | Lisinopril | 781 | 123 |
| Omeprazole | Omeprazole | 768 | 141 |
| Pantoprazole Sodium | Pantoprazole Sodium | 681 | 87 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 671 | 149 |
| Tamsulosin Hcl | Tamsulosin Hcl | 655 | 126 |
| Gabapentin | Gabapentin | 605 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 547 | 111 |
| Eliquis | Apixaban | 537 | 62 |
| Allopurinol | Allopurinol | 468 | 68 |
| Tramadol Hcl | Tramadol Hcl | 447 | 76 |
| Metformin Hcl | Metformin Hcl | 423 | 87 |
| Metoprolol Tartrate | Metoprolol Tartrate | 392 | 70 |
| Sertraline Hcl | Sertraline Hcl | 360 | 60 |
| Simvastatin | Simvastatin | 292 | 65 |
| Jardiance | Empagliflozin | 291 | 42 |
| Potassium Chloride | Potassium Chloride | 251 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 249 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 238 | 41 |
| Prednisone | Prednisone | 238 | 60 |
| Klor-Con M20 | Potassium Chloride | 237 | 23 |
| Finasteride | Finasteride | 230 | 35 |
| Famotidine | Famotidine | 228 | 31 |
| Meloxicam | Meloxicam | 223 | 30 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 217 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 217 | 34 |
| Donepezil Hcl | Donepezil Hcl | 216 | 31 |
| Trazodone Hcl | Trazodone Hcl | 196 | 36 |
| Metformin Hcl Er | Metformin Hcl | 191 | 41 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 189 | 37 |
| Spironolactone | Spironolactone | 178 | 34 |
| Carvedilol | Carvedilol | 173 | 30 |
| Xarelto | Rivaroxaban | 156 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 149 | suppressed |
| Lorazepam | Lorazepam | 148 | 46 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 142 | 34 |
| Montelukast Sodium | Montelukast Sodium | 135 | 29 |
| Fentanyl | Fentanyl | 127 | 12 |
| Pregabalin | Pregabalin | 122 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 118 | 46 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 116 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 116 | 18 |
| Valsartan | Valsartan | 110 | 27 |
| Digoxin | Digoxin | 107 | 12 |
| Memantine Hcl | Memantine Hcl | 107 | 17 |
| Bumetanide | Bumetanide | 105 | 16 |
| Jantoven | Warfarin Sodium | 105 | 16 |
| Ezetimibe | Ezetimibe | 104 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 103 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 93 | 25 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 93 | 39 |
| Ozempic | Semaglutide | 93 | 18 |
| Celecoxib | Celecoxib | 88 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 88 | 11 |
| Cephalexin | Cephalexin | 84 | 63 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 84 | 15 |
| Enalapril Maleate | Enalapril Maleate | 81 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 77 | 11 |
| Glimepiride | Glimepiride | 75 | 17 |
| Baclofen | Baclofen | 74 | suppressed |
| Mounjaro | Tirzepatide | 72 | suppressed |
| Klor-Con M10 | Potassium Chloride | 71 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 70 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 70 | 24 |
| Incruse Ellipta | Umeclidinium Bromide | 70 | suppressed |
| Myrbetriq | Mirabegron | 70 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 69 | 11 |
| Alendronate Sodium | Alendronate Sodium | 67 | 19 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 66 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 66 | suppressed |
| Levetiracetam | Levetiracetam | 65 | suppressed |
| Torsemide | Torsemide | 65 | suppressed |
| Lamotrigine | Lamotrigine | 62 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 30 |
| Amoxicillin | Amoxicillin | 59 | 36 |
| Fenofibrate | Fenofibrate Nanocrystallized | 57 | 11 |
| Nystatin | Nystatin | 56 | 20 |
| Gemfibrozil | Gemfibrozil | 54 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 54 | 12 |
| Risperidone | Risperidone | 54 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 53 | suppressed |
| Alprazolam | Alprazolam | 51 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 50 | 14 |
| Repatha Sureclick | Evolocumab | 49 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 48 | suppressed |
| Atenolol | Atenolol | 47 | 14 |
| Bupropion Xl | Bupropion Hcl | 47 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 47 | suppressed |
| Fenofibrate | Fenofibrate | 46 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 46 | 38 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 45 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 15 |
| Glipizide | Glipizide | 44 | suppressed |
| Lovastatin | Lovastatin | 44 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 43 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 42 | suppressed |
| Irbesartan | Irbesartan | 41 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 40 | suppressed |
| Carisoprodol | Carisoprodol | 39 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 39 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 38 | suppressed |
| Lidocaine | Lidocaine | 38 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 37 | suppressed |
| Mirtazapine | Mirtazapine | 37 | 11 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 37 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 35 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Latanoprost | Latanoprost | 34 | suppressed |
| Ramipril | Ramipril | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Lubiprostone | Lubiprostone | 33 | 32 |
| Ventolin Hfa | Albuterol Sulfate | 33 | 14 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 32 | 32 |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 20 |
| Paxlovid | Nirmatrelvir/Ritonavir | 31 | 31 |
| Primidone | Primidone | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Dutasteride | Dutasteride | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Timolol Maleate | Timolol Maleate | 29 | suppressed |
| Tradjenta | Linagliptin | 29 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 28 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 25 |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Methocarbamol | Methocarbamol | 27 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 27 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 20 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 26 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 25 | suppressed |
| Praluent Pen | Alirocumab | 25 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Xtampza Er | Oxycodone Myristate | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Ursodiol | Ursodiol | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 16 |
| Topiramate | Topiramate | 21 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 11 |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | suppressed |
| Nabumetone | Nabumetone | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Travoprost | Travoprost | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 18 | 18 |
| Levocarnitine | Levocarnitine | 18 | suppressed |
| Lumigan | Bimatoprost | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Mirabegron Er | Mirabegron | 18 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 11 |
| Insulin Aspart Flexpen | Insulin Aspart | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Paroxetine Cr | Paroxetine Hcl | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Victoza 3-Pak | Liraglutide | 16 | suppressed |
| Amantadine | Amantadine Hcl | 15 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Dupixent Syringe | Dupilumab | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $817.10 · 58 records | Amgen Inc. | Auvelity, CAMZYOS, CAPLYTA, Dexcom G6 Transmitter, ELIQUIS, EVENITY, INGREZZA, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, PAXLOVID, PROLIA, REPATHA, TRINTELLIX, The Cologuard Plus Collection Kit, VIBERZI, VRAYLAR, VYNDAQEL, Veozah, ZAVZPRET | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error